Table 5

Incidence of malignancies in the RA DMARD cohorts*

	BC	NDB	GPRD	NOAR	Sweden ERA
Total malignancies (excluding NMSC)	1274	NA^†	472	30	148
	1.77 (1.51 to 2.08)		0.67 (0.51 to 0.87)	0.73 (0.56 to 0.93)	0.71 (0.55 to 0.92)
Breast cancer	205	156	94	4	13
	0.34 (0.24 to 0.49)	0.28 (0.19 to 0.42)	0.16 (0.09 to 0.28)	0.14 (0.08 to 0.25)	0.11 (0.06 to 0.21)
Colorectal cancer	139	52	40	2	20
	0.14 (0.08 to 0.24)	0.06 (0.03 to 0.15)	0.05 (0.02 to 0.13)	0.05 (0.02 to 0.13)	0.06 (0.02 to 0.14)^‡
Lung cancer	218	116	109	4	23
	0.26 (0.17 to 0.39)	0.12 (0.07 to 0.22)	0.14 (0.08 to 0.25)	0.09 (0.04 to 0.18)	0.13 (0.07 to 0.23)
Lymphoma	94	35	41	3	11
	0.11 (0.06 to 0.21)	0.08 (0.04 to 0.17)	0.06 (0.02 to 0.14)	0.07 (0.03 to 0.16)	0.06 (0.02 to 0.14)

Values represent numbers of incident cancer cases and incidence rates (IR) per 100 person-years (95% CI). *Rates adjusted to the age and sex distribution of the abatacept clinical trial patients. ^†This outcome was not available for the NDB. ^‡The Sweden ERA cohort for the colorectal cancer analysis consists of 4295 patients rather than the 3703 used for the other malignancies.
BC, British Columbia RA Cohort; DMARD, disease-modifying antirheumatic drug; GPRD, General Practice Research Database; NDB, National Data Bank for Rheumatic Diseases; NMSC, non-melanoma skin cancer; NOAR, Norfolk Arthritis Register; RA, rheumatoid arthritis; Sweden ERA, Sweden Early Rheumatoid Arthritis Register.